Celgene Ready for its Quarterly Earnings Release

Facebook (FB)

JP Morgan (JPM)

AutoZone (AZO)

Yahoo (YHOO)

Apple (AAPL)

Medtronic Reports Fourth Quarter Earnings

Cracker Barrel Reports Earnings, Increases Guidance

Best ETFs For Facebook Exposure

Is Yum! Brands Closing in to Support?

Intuitive Surgical Bullish Signs

Celgene Ready for its Quarterly Earnings Release

Published on Wednesday, 25 January 2012 11:08 Written by Gerard Lerod

celg New York, January 25th (TradersHuddle.com) - Shares of Celgene Corporation (NASDAQ:CELG) are trading lower by -0.55% ahead of its quarterly earnings release. Celgene, the biopharmaceutical company focused on cancer treatments is expected to release its quarterly results on January 26^th.

Wall Street Analysts consensus calls for a profit of $1.06 a share on $1.29 billion revenue.

Celgene estimates have a range of $0.09 a share. The high estimate calls for profit of $1.1 a share and the low estimate is calling for a profit of $1.01 a share, a year ago for the quarter the company reported $0.73 a share.

Celgene Corporation (NASDAQ:CELG) is a global biopharmaceutical company. The Company focuses on the development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Celgene Corporation (CELG): Today's Featured Health Care Loser - TheStreet.com
Celgene Corporation (CELG): Today's Featured Drugs Loser - TheStreet.com
Celgene Corporation (CELG): Today's Featured Drugs Loser - TheStreet.com
Separating the Bargains From the Busts - TheStreet.com
Earnings Recap for April 26, 2012 - Benzinga
A Peek Into The Market Before The Trading Starts - Benzinga
Epizyme Forms Strategic Partnership wit Celgene Corporation - Benzinga
Analysts Actions: DOV, CELG, JCI - TheStreet.com
I Know Lazy When I See It - TheStreet.com
Celgene Stock Hits New 52-Week High (CELG) - TheStreet.com

Real Money Pro from TheStreet: Headlined by legendary hedge fund manager Doug Kass, our team of market technicians and professional traders hand you unique perspectives and breakthrough investment opportunities. Access this exciting service -- Real Money Pro -- FREE, right now!